top of page
JARDIANCE (empagliflozin) is a medication prescribed to treat type 2 diabetes mellitus. JARDIANCE is prescribed in combination with diet and exercise to help improve blood glucose control. JARDIANCE may also be prescribed to reduce the risk of cardiovascular death in people with both type 2 diabetes mellitus and cardiovascular disease. JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 is a protein on the surface of certain kidney cells. When the kidney filters blood to urine, glucose is filtered out but pulled back into the blood by SGLT2. JARDIANCE blocks SGLT2, so when glucose is filtered into the urine, it cannot be pulled back into the blood. This lowers blood glucose and helps to treat type 2 diabetes mellitus. Fact Table Formula C23H27ClO7 License EU EMA, US DailyMed Bioavailability 78% Legal status Rx-Only Chemical Name Empagliflozin Elimination half-life 12.4 hours Dosage (Strength) 10mg, 25mg Pregnancy Not recommended Brands Jardiance Protein binding 86.2% PubChem CID 11949646 MedlinePlus a614043 ChEBI 82720 ATC code A10BK03 DrugBank DB09038 KEGG D10459 Routes of administration By mouth (tablets)

Jardiance (Empagliflozin)

  • Take 10 mg once daily with or without food. JARDIANCE should be taken in the morning. The dose can be increased to 25 mg once daily as needed.
bottom of page